Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the valencian community of Spain

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Cebrián Cuenca, Ana M ^a   Díez Domingo, Javier ^b   San Martín Rodríguez, María ^c   Puig Barberá, Joan ^b   Navarro Pérez, Jorge ^d,e  

^a Centro de Salud Nazaret   (Spain)

^b Centro Superior de Investigaciones en Salud Pública de Valencia CSISP   (Spain)

^c Sanofi Pasteur MSD   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; FEMALE; FOLLOW UP; HEALTH CARE COST; HERPES ZOSTER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; RASH; SPAIN; ECONOMICS; MIDDLE AGED; PRIMARY HEALTH CARE; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEALTH CARE COSTS; HERPES ZOSTER; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SPAIN;

EID: 80055047272     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-302     Document Type: Article

References (46)

1. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002, 360:678-682.
2. Ly Pen D, Manzano Espinosa L. Neuralgia postherpética: incidencia, prevención y tratamiento. Rev Clin Esp 2007, 207:23-28.
3. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001, 32:1481-1486.
4. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardmand KD, Williams HM, Hongyuan Zhang J, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, , et al. for the Shingles Prevention Study Group A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284. for the Shingles Prevention Study Group.
5. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2002, 125:651-669.
6. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004, 4:26-33.
7. Hope-Simpson RE. The nature of Herpes Zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20.
8. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, Seward JF. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005, 5:68-77.
9. De Melker H, Berbers G, Hahné S, Rümke H, van den HS, De Wit A, Boot H. The epidemiology of varicella and herpes zoster in The Netherlands: Implications for varicella zoster virus vaccination. Vaccine 2006, 24:3946-3952.
10. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005, 19:2002-2007.
11. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005, 133:245-253.
12. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005, 6:356-363.
13. Cebrián-Cuenca AM, Díez-Domingo J, Rodríguez MS, Puig-Barberá J, Navarro-Pérez J. "Herpes Zoster Research Group of the Valencian Community". Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian Community (Spain). BMC Fam Pract 2010, 6:11-33.
14. García Cenoz M, Castilla J, Montes Y, Morán J, Salaberri A, Elía F, Floristán Y, Rodrigo I, Irisarri F, Arriazu M, Zabala A, Barricarte A. Incidencia de la varicela y el herpes zoster antes de la introducción de la vacunación sistemática infantil en Navarra, 2005-2006. An Sist Sanit Navar 2008, 31:71-80.
15. Pérez-Farinós N, Ordobás M, García-Frenández C, García-Comas L, Cañellas S, Rodero I, Gutiérrez-Rodríguez A, García-Gutiérrez J, Ramírez R. Varicella and Herpes zoster in Madrid, based on the Sentinel General Practitioner Network: 1997-2004. BMC Infect Dis 2007, 7:59-64.
16. McGregor RM. Herpes zoster, chicken-pox, and cancer in general practice. BMJ 1957, 1:84-87.
17. Fleming DM, Norbury CA, Crombie DL. Annual and seasonal variation in the incidence of common diseases. 1991, Birmingham: Royal College of General Practitioners.
18. McCormick A, Fleming D, Charlton J. Morbidity statistics from general practice: 4th national study 1991-92. A study carried out by the Royal College of General Practitioners, the Office of Population Censuses and Surveys, and the Department of Health. 1995, London: HM Stationery Office.
19. Chidiac C, Bruxelle J, Daures JP, Hoang Xuan T, Morel P, Leplège A, El Hasnaoui A, de Labareyre C. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001, 33:62-69.
20. Di Luzzio Paparati U, Arpinelli F, Viscona G. Herpes zoster and its complications in Italy: an observational survey. J Infection 1999, 38:116-119.
21. Opstelten W, Van Essen GA, Schellevis F, Verheij T, Moons K. Gender as independent risk factor for herpes zoster: a population based study. Ann Epidemiol 2006, 16:692-695.
22. Brisson M, Edmunds WJ. Epidemiology of varicella zoster virus in England and Wales. J Med Virol 2003, 70:9-14.
23. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: A prospective population based study. Vaccine 2006, 24:1308-1314.
24. Gautier A, Breuer J, Carrington D, Martin M, Rèmy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137:38-47.
25. Czernichow S, Dupuy A, Flahault A, Chosidow O. Herpes zoster: incidence study among Sentinel practitioners. Ann Dermatol Venereol 2001, 128:497-501.
26. Richards P. Shingles in one family practice. Arch Fam Med 1996, 5:42-46.
27. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy L. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82:1341-1349.
28. Insinga R, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of Herpes Zoster in a United States Administrative Database. J Gen Intern Med 2005, 20:748-753.
29. Watson CP, Watt VR, Chipman M, Birkett N, Evans RJ. The prognosis with postherpetic neuralgia. Pain 1991, 46:195-9.
30. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996, 67:241-51.
31. Helgason S, Petursson G, Gudmundsson S, Sigurdosson JA. Prevalence of postherpetic neuralgia after a single episode of herpes zoster: prospective study with long term follow up. BMJ 2000, 321:1-4.
32. Dworkin RH, Schmader KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. Herpes zoster and postherpetic neuralgia, second revised and enlarged edition 2001, 11:39-64. Amsterdam: Elsevier, Watson CPN, Gershon AA.
33. Ley 15/2007, de 27 de diciembre, de la Generalitat Valenciana, de Presupuestos para el ejercicio 2008 (DOCV 5670, de 31 de diciembre de 2007).
34. Vademécum Internacional Medicom. Madrid 2007, 48, Vademécum Internacional.
35. Website of Spanish National Statistics Institute, Encuesta de Trimestre Laboral. , http://www.ine.es/jaxi/menu.do?type=pcaxis&path=/t22/p187&file=inebase&N=&L=
36. Website of Conselleria de Sanitat de la Generalitat Valenciana. , http://www.san.gva.es/prof/dgf/farmacia/receta.html
37. Website of Spanish National Statistics Institute. , http://www.ine.es/jaxi/tabla.do?path=/t20/e245/p04/a2007/l0/&file=00000003.px&type=pcaxis&L=0
38. Gil A, Gil R, Alvaro A, San Martín M, González A. Burden of Herpes Zoster requiring hospitalization in Spain during a seven-year period (1998-2004). BMC Infect Dis 2009, 9:55-60.
39. Dieleman JP, Kerklaan J, Huygen FJ, Bouma PA, Sturkenboom MC. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008, 137:681-688.
40. Parrutti G, Tontodonati M, Rebuzzi C, Polilli E, Sozio F, Consorte A, Agostinone A, Di Masi F, Congedo G, D'Antonio D, Grnachelli C, D''Amario C, Carunchio C, Pippa L, Manzoli L, Volpi A, . VZV Pain Study Group Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy. BMC Medicine 2010, 8:58-68. VZV Pain Study Group.
41. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain 2009, 10:447-485.
42. Davies L, Cossins L, Bowsher D, Drummond M. The cost of treatment for post-herpetic neuralgia in the UK. Pharmacoeconomics 1994, 6:142-148.
43. Edmunds J, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19:3076-3090.
44. Yawn B, Itzler R, Wolan P, Pellissier J, Sy L, Saddier P. Health care utilization and cost burden of herpes zoster in a community population. Mayo Clin Proc 2009, 84(9):787-94.
45. Schieber GJ, Poullier JP. International health care spending. Health Aff (Millwood) 1986, 5:111-122.
46. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpaa ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Pavan-Langston D, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, Wijck van AJ, Wallace MS, Wassilew SW, Whitley RJ. Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44(Suppl 1):S1-26.